|Bid||5.33 x 800|
|Ask||5.55 x 900|
|Day's Range||5.32 - 5.75|
|52 Week Range||4.41 - 6.69|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.92|
Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Victoria, British Columbia-based company said it had a loss of 21 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
VICTORIA, British Columbia-- -- AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule Phase II data for the treatment of dry eye expected in January 2019 Phase II FSGS Trial ongoing Richard M. Glickman announces his intention to retire as CEO next year, upon identification and appointment of an appropriate successor Aurinia Pharmaceuticals Inc. has released its financial ...
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries. “We are elated by the significant interest this trial has garnered around the globe, which reinforces the need for new treatment options for patients living with lupus nephritis,” said Richard M. Glickman, Aurinia’s Chairman and Chief Executive Officer.
Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.
Aurinia Pharmaceuticals Inc., (AUPH)(AUP.TO) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company's business on Thursday, September 6 at 10:50am ET. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference.
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural ...
Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Victoria, British Columbia-based company said it had a loss of 19 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Aurinia Pharmaceuticals Inc’s (TSE:AUP): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada,Read More...
Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.
Since last year, Aurinia Pharmaceuticals (NASDAQ:AUPH) has moved very little on the stock market. News of the launch of a mid-stage study, along with a quarterly earnings report before that, failed to ignite or hurt AUPH stock by much. On July 11, Aurinia launched a mid-stage Phase 2 clinical study that evaluates its drug, Voclosporin, for treating dry eye syndrome (or DES).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). VOS, which is a proprietary nanomicellar formulation, enables high concentrations of voclosporin to be incorporated into a clear aqueous, preservative-free solution for local delivery to the ocular surface. This patented formulation has the potential to result in improved efficacy, dosing frequency, and tolerability versus the current treatments for DES.
Under observation are these four equities: Ardelyx Inc. (NASDAQ: ARDX), Array BioPharma Inc. (NASDAQ: ARRY), Audentes Therapeutics Inc. (NASDAQ: BOLD), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its Phase II trial in focal segmental glomerulosclerosis (FSGS). The first patients have rolled over into the AURORA 2 extension study from the AURORA Phase III clinical trial for lupus nephritis.